ArticleScientific reports2026
Cerebellar oligodendrocytic α-synuclein pathology and dentate nucleus neuronal hypertrophy in Parkinson's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cellular prion protein levels modulate nigrostriatal vulnerability to α-synuclein oligomers in Parkinson's disease.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic Parkinson's disease (iPD) research has historically prioritized basal ganglia dysfunction and neuronal Lewy body pathology, often overlooking cerebellar and non-neuronal cells contributions. This study investigates cerebellar neuropathology in iPD, specifically focusing on neuronal and non-neuronal cells of the dentate nucleus (DN) and its adjacent white matter (DN-WM). We systematically assessed autopsy-confirmed iPD brains vs. age-matched controls using immunohistochemistry and stereology-based morphometry methods. The study evaluated α-synuclein pathology, other common age-related co-occurring pathologies (β-amyloid, Tau, neuroinflammation), myelin integrity (Luxol-Fast-Blue), and neuronal volumetric changes in the DN of the cerebellum. In iPD brains, we identified intracytoplasmic α-synuclein inclusions within oligodendrocytes across the peri-DN-WM. These inclusions were distinct from classic neuronal Lewy bodies (dense core with clearer halo), which were notably absent in the DN neurons. Concomitantly, we observed myelin rarefaction in the DN and the around WM area. Moreover, stereology-based morphometric analysis revealed a significant hypertrophy of DN neuronal soma (p < 0.05), nuclei (p < 0.0001), and nucleoli (p < 0.0001) in iPD vs. C subjects, suggesting a heightened metabolic state or compensatory stress response. These findings are novel and suggest that oligodendroglial α-synucleinopathy may be a contributing factor to cerebellar abnormalities and degeneration in iPD. Due to the recent identification of direct pathways between the DN and basal ganglia in primates and the DN primary dopaminergic modulatory function, these outcomes are of a special pathophysiological relevance. In fact, we hypothesize that this oligo-synucleinopathy WM deterioration compromises the glial-neuronal metabolic coupling and physiological transmission along the cerebello-basal ganglia-cortical loops. Moreover, these alterations could contribute to explain the broader spectrum motor and non-motor symptomatology observed in specific iPD subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.